Welcome to our dedicated page for SS Innovations International news (Ticker: $SSII), a resource for investors and traders seeking the latest updates and insights on SS Innovations International stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SS Innovations International's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SS Innovations International's position in the market.
SS Innovations has announced that its SSi Mantra Surgical Robotic System has been used to perform over 100 robotic cardiac surgeries, signaling significant market expansion. The SSi Mantra, featuring a unique fifth arm capability, has been utilized in more than 1000 procedures globally. The company anticipates FDA and CE Mark approvals by early 2025, further enhancing its market position. The global cardiac surgery device market is projected to grow from $17.1 billion in 2023 to $24.9 billion by 2030, while the surgical robotics market is expected to increase from $78.8 billion in 2022 to $188.8 billion by 2032. SS Innovations, through its comprehensive robotic cardiac surgery program, aims to provide less invasive, lower cost, and superior outcomes for patients worldwide.
SS Innovations International, Inc. (SSII) achieved a significant milestone by successfully performing the first infant pyeloplasty using its flagship SSi Mantra Surgical Robotic System. The procedure, led by Dr. Chandra Mohan Vaddi in Hyderabad, India, was a success on a 12-month-old baby. The SSi Mantra is the first surgical system made in India and is cost-effective with regulatory approval in India, Guatemala, and Indonesia. The system has been used in over 1000 surgical procedures across various specialties. SS Innovations is seeking regulatory approval in the US and EU by late 2024 or 2025.